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ABSTRACT
Facioscapulohumeral muscular dystrophy (FSHD) is a genetically
dominant myopathy caused by mutations that disrupt repression of
the normally silent DUX4 gene, which encodes a transcription factor
that has been shown to interfere with myogenesis when
misexpressed at very low levels in myoblasts and to cause cell
death when overexpressed at high levels. A previous report using
adeno-associated virus to deliver high levels of DUX4 to mouse
skeletal muscle demonstrated severe pathology that was suppressed
on a p53-knockout background, implying that DUX4 acted through
the p53 pathway. Here, we investigate the p53 dependence of DUX4
using various in vitro and in vivo models. We find that inhibiting p53
has no effect on the cytoxicity of DUX4 on C2C12myoblasts, and that
expression of DUX4 does not lead to activation of the p53 pathway.
DUX4 does lead to expression of the classic p53 target geneCdkn1a
(p21) but in a p53-independent manner. Meta-analysis of 5 publicly
available data sets of DUX4 transcriptional profiles in both human and
mouse cells shows no evidence of p53 activation, and further reveals
that Cdkn1a is a mouse-specific target of DUX4. When the inducible
DUX4mousemodel is crossed onto the p53-null background, we find
no suppression of the male-specific lethality or skin phenotypes that
are characteristic of the DUX4 transgene, and find that primary
myoblasts from this mouse are still killed by DUX4 expression. These
data challenge the notion that the p53 pathway is central to the
pathogenicity of DUX4.
KEY WORDS: Facioscapulohumeral muscular dystrophy,
Myopathy, DUX4, p53
INTRODUCTION
Facioscapulohumeral muscular dystrophy (FSHD) affects over
25,000 people in the USA alone, making it one of the most prevalent
genetic diseases. The genetic mutation underlying FSHD is usually
a reduction in the copy number of a macrosatellite repeat on
chromosome 4 referred to as D4Z4 (van Deutekom et al., 1993;
Wijmenga et al., 1992). This repeat is GC-rich, highly methylated
and normally subjected to repeat-induced silencing, which is
disrupted in an allele-specific manner by contractions to 10 or fewer
copies (van Overveld et al., 2003) or is disrupted on all D4Z4
repeats owing to mutation in the chromatin protein SMCHD1 (de
Greef et al., 2009; Hartweck et al., 2013; Lemmers et al., 2012).
When silencing at D4Z4 breaks down, an RNA transcript encoding
the DUX4 protein (Gabriëls et al., 1999) is expressed. The presence
of a poly(A) signal downstream of the D4Z4 repeats on
chromosome 4 (chr4) (Dixit et al., 2007) leads to DUX4
expression and explains why disease is associated only with
contractions of the D4Z4 repeats on chr4, and only on specific
terminal 4q (4qter) alleles, so-called permissive alleles, which
harbor the poly(A) signal (Lemmers et al., 2004, 2010). The DUX4
protein has been observed by immunostaining of cultured FSHD
myoblasts, which show infrequent, possibly episodic, expression
(Jones et al., 2012; Snider et al., 2010), and differentiated myotubes,
which show more prevalent expression (Block et al., 2013; Rickard
et al., 2015).
Mechanisms of DUX4-mediated pathology are currently being
actively investigated. At high levels of expression, DUX4 causes
toxicity that leads to cell death of myoblasts (Bosnakovski et al.,
2008; Kowaljow et al., 2007), whereas, at low levels of
expression, it impairs myogenic differentiation (Dandapat et al.,
2014) and sensitizes cells to oxidative stress (Bosnakovski et al.,
2008). A mouse model allowing doxycycline-regulated DUX4
expression has recapitulated these phenotypes in primary
myoblasts (Dandapat et al., 2014) while also having several
non-muscle related phenotypes due to low basal levels of DUX4
expression in the absence of doxycycline (Dandapat et al., 2016).
Other animal model work includes a mouse carrying human D4Z4
repeats (Krom et al., 2013), which showed some evidence of
sporadic DUX4 expression but no myopathy, and adeno-
associated viral (AAV) vector-mediated delivery of DUX4 to
zebrafish and mouse skeletal muscle, which showed profound
myopathy (Wallace et al., 2011). This work by Wallace and
colleagues implicated the p53 pathway in DUX4 pathology, as
the p53-knockout mouse background suppressed AAV-DUX4
toxicity. The linkage to p53 is compelling because this pathway
has the potential to push cells into apoptosis; however, precisely
how DUX4 would activate p53 is not clear. The immediate targets
of the DUX4 transcription factor include genes with regulatory
elements containing the sequence TAATCTAATCA (Geng et al.,
2012; Zhang et al., 2015), or variants thereof. ChIP-sequencing
(ChIP-seq) has identified many genomic targets (Choi et al., 2016;
Geng et al., 2012) and, at the majority of these, DUX4 displaces
nucleosomes and recruits p300 and/or CBP through its
C-terminus, thereby promoting acetylation of histone H3 and
activation of transcription (Choi et al., 2016).Received 18 March 2017; Accepted 26 July 2017
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Here, we directly test the dependence on p53 of the pathogenic
phenotypes of DUX4 expression by inhibiting p53 in cell lines
while DUX4 is expressed, and by establishing the doxycycline-
inducible iDUX4[2.7] mouse model on the p53-knockout
background. These experiments reveal that p53 is not necessary
for DUX4-mediated pathology, neither in myoblasts nor in other
tissues.
RESULTS
Previously, overexpression of Pax3 or Pax7 was shown to reduce the
toxicity of DUX4 to C2C12 mouse myoblasts (Bosnakovski et al.,
2008). To see to what extent inhibiting p53 could similarly reduce
DUX4 toxicity, we transduced iC2C12-DUX4 cells, which are
immortalized mouse myoblasts engineered for doxycycline-
inducible DUX4 expression, with retroviral vectors expressing
several constructs known to interfere with p53: a dominant-negative
p53 (R175Hmutation), MDM2 (Momand et al., 1992) and TRIM24
(Allton et al., 2009). Overexpressing cell lines were established and
cells were exposed to two different doses of doxycycline, both of
which resulted in significant cell killing in the absence of
overexpression (empty-vector control). Notably, although the
positive controls, Pax3 and Pax7, were substantially protected
from apoptosis at 24 h, cells transduced with the three individual
p53 inhibitors did not show a reduced death rate compared to empty
vector (Fig. 1A). This indicates that, in this system, p53 is not a
relevant player in the cell death phenotype.
Because C2C12 cells are an immortalized cell line, highly
selected for proliferation, we investigated whether the p53 pathway
was actually functional in these cells. We therefore treated C2C12
cells with Adriamycin, which causes DNA damage and induces the
p53 response, and compared these to wild-type mouse myoblasts
treated with Adriamycin. In both cases, Adriamycin treatment
resulted in stabilization and accumulation of p53 (Fig. 1B). We also
evaluated iC2C12-DUX4 cells, which were treated with
Adriamycin to induce DNA damage or doxycycline to induce
DUX4 expression. Although DUX4 was clearly induced by
doxycycline, only Adriamycin induced a p53 response: DUX4
did not.
Finally, because the presumed linkage between DUX4 and the
p53 pathway was originally suspected owing to upregulation of a
strong p53 target gene, Cdnk1a (p21), we investigated the
regulation of Cdkn1a in this system (Fig. 1C). We observed that
both Adriamycin treatment and doxycycline treatment led to the
upregulation of Cdkn1a. This indicates that DUX4 induces Cdkn1a
in a p53-independent manner, i.e. Cdkn1a is likely a DUX4 target
gene in the mouse system.
To expand this analysis to a larger set of p53 pathway genes, we
evaluated our and others’ published transcriptional profiling data
from 5 independent studies, 2 in mouse cells and 3 in human cells
(Fig. 2). In each case, the set of genes annotated as DUX4 targets
was found to be strongly upregulated. By contrast, the set of genes
annotated as p53 targets showed no discernable upregulation, and
there was even a downregulation of certain p53 targets (e.g. Ccnd1/
CCND1, Trp53/TP53). This demonstrates that the published
transcriptional profiling data available do not support the notion
that DUX4 induces the p53 pathway.
We have previously generated a mouse model with a
doxycycline-inducible 2.7-kb DUX4 transgene (Dandapat et al.,
2014, 2016), referred to as iDUX4[2.7]. One of the interesting
features of this mouse is that the very low basal level of expression
from the Tet-on promoter in the absence of doxycycline leads to
various non-muscle phenotypes, especially in males, of which 80%
die as embryos, with the remaining 20% being severely runted and
all dying before 6 weeks of age. Females are less severely affected
and can thus propagate the strain – because the transgene is X-
linked, X-inactivation diminishes the phenotype in females. We
reasoned that, if p53 were necessary for the pathological effects of
DUX4 on embryonic cell types, then, on a p53 knockout
background, males ought to be born at normal ratios and ought to
be relatively healthy compared to siblings with a functional copy of
p53. We therefore crossed the iDUX4[2.7] transgene onto the p53-
knockout background. Female carriers were obtained that were
homozygous for the p53 knockout and these were bred to male p53
heterozygotes. We genotyped 65 progeny from this backcross and
obtained no DUX4+ males, neither on the p53-knockout nor on the
heterozygous background (Fig. 3). Thus, absence of p53 has no
Fig. 1. The p53 pathway is not relevant to DUX4 activity in vitro. (A) Viability
of iC2C12-DUX4 cell lines, which express DUX4 in response to different doses
of doxycycline and other factors constitutively from the murine stem cell
virus (MSCV) long terminal repeat (LTR), or empty vector (EV). Viability
in the presence of doxycycline (Dox) is normalized to that in its absence.
n=8 biological replicates (separate wells) per group. Data presented as
means±s.e.m. t-test: ****P<0.0001. (B) Western blots for DUX4 (top), p53
(middle) and GAPDH (bottom). Representative western blot image from 1 of 4
biological replicates is shown. (C) RTqPCR for Cdkn1a expression under
various conditions, normalized to Gapdh expression. Data presented as
means±s.e.m., n=3, t-test: ****P<0.0001.
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effect on the pathological effects of DUX4 on development in the
iDUX4[2.7] strain.
Although no males were produced from the backcross described
above, we did eventually obtain live-born p53 iDUX4[2.7]
knockout males from F1 crosses to Rosa-rtTA p53 double-
heterozygous males, and these rare animals displayed the severe
runting and skin phenotypes (flaky skin, alopecia and puffy eyelids)
typical of the iDUX4[2.7] mouse (Dandapat et al., 2014). Thus, p53
is not necessary for the pathological effects of DUX4 on non-
muscle tissues.
To determine whether DUX4 would be cytotoxic to muscle cells
in the absence of p53, we established primary cell cultures from
muscle tissue of these iDUX4[2.7]; p53 knockout animals. Primary
muscle cells were sorted into myogenic and fibro/adipogenic
fractions by flow cytometry for VCAM/Itga7 and PDGFRα,
respectively. These sorted primary cultures were then exposed to
doxycycline over a series of doses to induce DUX4 expression to
different levels. DUX4 expression was clearly cytopathic (Fig. 4A)
and caused a dose-dependent loss of cellular viability in myoblasts
(Fig. 4B). The same was observed for fibro/adipogenic progenitors
(Fig. 4A,B) on the p53-knockout background. Thus, in the absence
of p53, DUX4 is still cytotoxic, to both myogenic and fibro/
adipogenic progenitors.
DISCUSSION
Using both the inducible C2C12 cell culture system (iC2C12-
DUX4 cells), in which it was originally demonstrated that DUX4
was pathogenic to myogenic progenitors (Bosnakovski et al., 2008),
and the iDUX4[2.7] mouse model (Dandapat et al., 2014), we find
no evidence for p53 involvement in DUX4 pathogenicity. This
lack of involvement of p53 is also supported by transcriptional
profiling data from 5 independent publications. In addition, a
recent report investigating shRNA suppressors of DUX4-mediated
cytopathology found that a p53-knockdown vector did not suppress
DUX4 pathology (Shadle et al., 2017). Interestingly, in our studies,
the lack of p53 dependence applies to phenotypes caused by very
low basal levels of DUX4 expression, as the developmental effects
and runting are thought to be, as well as overt cytotoxicity in
primary or immortalized cells, which is the result of high-level
DUX4 expression.
With this in mind, it needs to be pointed out that the original study
implicating p53 in DUX4 toxicity (Wallace et al., 2011) made use of
a very different experimental system with vastly higher levels of
DUX4 expression: recombinant AAV-vector-mediated production.
The levels of DUX4 expression achieved in a cell infected with
multiple copies of DUX4 driven from the CMV promoter are much
higher than those in which DUX4 is expressed from its endogenous
DUX4 in C2C12 Cells (Whiddon et al., 2017)
DOX36h 36h 36h
DOX14h 14h 14h24h 24h 24h24h 24h 24h DOX6h 6h 6h
Lo
g2
 (N
or
m
al
iz
ed
 F
PK
M
)
Lo
g2
 (N
or
m
al
iz
ed
 F
PK
M
)
Lo
g2
 (N
or
m
al
iz
ed
 F
PK
M
)
DUX4 in C2C12 Cells (Bosnakovski et al., 2008)
DUX4 in Myoblasts (Geng et al., 2012) DUX4 in MB135 Cells (Jagannathan et al., 2016)DUX4 in LHCNM2 Cells (Choi et al., 2016)
DOX4h 4h 4h 12h 12h 12h
Lo
g2
 (N
or
m
al
iz
ed
 E
xp
re
ss
io
n)
Wfdc3
Myo1g
Azi2
Mapkbp1
Cdkn1a
Apaf1
Bax
Ccnd1
E2f1
Mdm2
Rb1
Trp53
Casp3
6
8
10
12
14 Wfdc3
Myo1g
Azi2
Mapkbp1
Cdkn1a
Apaf1
Bax
Ccnd1
E2f1
Mdm2
Rb1
Trp53
Casp3
0
2
4
6
8
A B
C D E
ZSCAN4
LEUTX
TRIM43
KHDC1L
CDKN1A
APAF1
BAX
CCND1
E2F1
MDM2
RB1
TP53
CASP3
0
2
4
6
8
ZSCAN4
LEUTX
TRIM43
KHDC1L
CDKN1A
APAF1
BAX
CCND1
E2F1
MDM2
RB1
TP53
CASP3
0
5
10
ZSCAN4
LEUTX
TRIM43
KHDC1L
CDKN1A
APAF1
BAX
CCND1
E2F1
MDM2
RB1
TP53
CASP3
8
10
12
14
Lo
g2
 (N
or
m
al
iz
ed
 E
xp
re
ss
io
n)Lenti
Fig. 2. Lack of transcriptional response to DUX4 in p53 target genes. (A) Heatmap of log2 expression values for microarray data for DUX4 targets in mouse
C2C12 cells upon doxycycline (DOX)-inducedDUX4 expression. Each replicate is shown independently and the amount of time between induction and harvest is
indicated above each column. DUX4 targets (upper panels) and Cdkn1a, which is both a DUX4 target and a p53 target in mouse cells (middle panel), are
reproducibly upregulated, whereas the remaining traditional p53 targets show no discernable pattern of regulation (lower panels). (B) Heatmap of log2 expression
values for RNA-seq data for DUX4 targets, grouped as in A. (C) Microarray experiments in human myoblasts cells. Gene lists are grouped as in A and B, with the
exception of Cdkn1a, which is grouped with the p53 targets as it is not a DUX4 target in human cells. (D) RNA-seq experiments in the human LHCNM2 cell line.
(E) RNA-seq experiments in the human MB135 cell line. Note that, in C, D and E, p53 targets are not induced (lower panels) despite the strong induction of
DUX4 targets (upper panels). See the reference list for references stated in the figures.
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promoter from a single (terminal) D4Z4 repeat in FSHD. It is
possible that, at these exceptionally high levels of expression, the
p53 pathway does in fact become necessary for some aspect of
extreme pathology; however, the relevance of such high levels of
expression is debatable. The nature of the muscle damage seen in the
AAV model is quite distinct from that seen in FSHD, and DUX4
expression is in fact quite difficult to detect in biopsies of FSHD
muscle, to the point where the most reliable readout of its expression
in biopsies is its target-gene fingerprint (Yao et al., 2014). It is also
conceivable that some aspect of the AAV experimental system
combines with the effect of DUX4 to make the pathology more
severe than it would otherwise have been, and that the p53 effect
ascribed to DUX4was in fact downstream of the cellular response to
AAV infection. A final difference to keep in mind is that the
experiments presented in the current study do not specifically
investigate p53 in adult myofibers in vivo. It is theoretically possible
that p53 is uniquely downstream of DUX4 in adult myofibers, and
thus participates in the DUX4 response only in that cell type.
However, transcriptional studies on FSHD patient biopsies have not
highlighted p53 as a significantly altered pathway (Celegato et al.,
2006; Osborne et al., 2007; Winokur et al., 2003; Yao et al., 2014).
Regardless of the reason for the different results, the studies
presented here clearly demonstrate that p53 is not necessary for the
cytotoxicity of DUX4, and that the p53 pathway is not generally
activated by DUX4.
MATERIALS AND METHODS
Mice
Animal work was conducted under a protocol approved by the University of
Minnesota Institutional Animal Care and Use Committee. The p53 mutant
allele used in these studies was obtained from Jackson Laboratories (strain
008651) and carries a floxed stop codon upstream of a dominant-negative
(R270H) p53 mutant. In the absence of Cre, no functional p53 is produced;
thus, as used in the current study, it is a null allele. Mice homozygous for
this allele eventually succumbed to thymic lymphomas, as predicted for a
p53 null.
Cell culture
The iC2C12-DUX4 cell line (recently validated and tested for
contamination) was cultured in high-glucose Dulbecco’s modified Eagle
media (DMEM) supplemented with 20% fetal bovine serum (FBS, Atlanta
Biologicals), L-glutamine and sodium pyruvate (Gibco), penicillin and
streptomycin (from a 100× stock from Gibco) at 37°C in 5% CO2.
Primary mouse myoblasts and muscle fibroblasts were isolated and
expanded as previously described (Arpke et al., 2013; Dandapat et al.,
2014). Briefly, hindlimb muscles from 3-week-old mice were dissected
under sterile conditions, minced using razor blade and digested with
collagenase type II (Gibco, Grand Island, NY, 17101-015) and dispase
(Gibco, 17105-041). Single-cell suspensions were plated in T75 dishes in F-
10/Ham’s (HyClone) medium containing 20% FBS (HyClone), 50 ng μl−1
human basic fibroblast growth factor (Peprotech), 1% penicillin/
streptomycin (Gibco) and 1% GlutaMAX (Gibco), and cultured at 37°C
at 5% O2, 5% CO2 for 5 days. From the expanded primary cells, myoblasts
and fibroblasts were separated by flow cytometry for Itga7 and PDGFRα
expression, respectively. Cells were trypsinized (0.25%, Gibco) and stained
with PDGFRα phycoerythrin (PE) (e-Biosciences, clone: APA5, dilution:
1:200) and Itga7 allophycocyanin (APC, Ablab, R2F2, dilution: 1:200)
Fig. 3. p53 status does not impact survival of iDUX4[2.7] animals to birth.
Summary of genotypes observed from a backcross of p53-knockout males to
p53 heterozygous females carrying the iDUX4[2.7] transgene. Expected
values are based on total numbers, assuming no loss of viability. Note that no
male carriers were observed, neither in the heterozygous nor homozygous
p53-null state. Testing the hypothesis that p53 affects survival, using the 4
classes of male progeny, P=0.74 (Fisher’s exact test); therefore, the null
hypothesis (p53 does not affect survival of iDUX4[2.7] mice) is assumed.
‘D’=presence of iDUX4[2.7] transgene, versus Y=Y-chromosome or ‘+’=wild-
type X-chromosome; p=p53-null versus ‘+’=wild-type p53 allele, i.e. p/p=null
for p53.
Fig. 4. Muscle progenitors are killed by DUX4 on the p53 mutant background. (A) Photomicrographs of homozygous fibro/adipogenic (PDGFRα+) and
myogenic (Itga7+) progenitors from male 3-week-old p53-knockout mice; (top) iDUX4[2.7] mice under control expansion conditions or (bottom) iDUX4[2.7] mice
exposed to doxycycline (Dox) to induce DUX4 expression. Scale bars: 100 µm. (B) Viability assay for the same cells, exposed to different doses of doxycycline;
n=8. Luminescence detects ATP,measuring viability of the cultures. Doxycycline induces loss of viability in bothmyoblasts and fibro/adipogenic progenitors. Data
presented as means±s.e.m. (P<0.0001 by two way ANOVA/Sidak post hoc for both studies).
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antibodies in FACS staining medium (PBS, 1% FBS). Single-positive
FACS-sorted populations were expended in the same medium and
conditions used for initial primary culture.
Expression constructs
We constructed the expression vector pMSCViGFP.GW, a Gateway-
cloning-compatible retroviral expression vector, by subcloning the
Gateway exchange cassette (Invitrogen) into XhoI/BglII-cut pMSCV-ires-
GFP. The cDNAs for p53R175H, TRIM24 and MDM2 were amplified by
PCR with flanking attB sites and subcloned by Gateway cloning into
MSCViGFP.GW.
Establishing overexpressing cell lines
Retroviral expression constructs were co-transfected with the packaging
constructs pCL-Eco (Naviaux et al., 1996) into 293T cells using FuGENE 6
transfection reagent (Roche). Virus-containing supernatants were collected
48 h later, filtered (0.45 μm) and used directly to transduce iC2C12-DUX4
cells. Constitutively overexpressing cell lines were obtained by FACS-
sorting GFP+ cells.
Cell death inhibition assays
Cell viability was analyzed as previously described (Bosnakovski et al.,
2014). Briefly, myoblasts and fibroblasts were plated in 96-well plates at
3000 cells per well in proliferation medium and treated with different
concentrations of doxycycline for 72 h. Medium was removed from the
plate; 100 µl working (diluted 1:3 with PBS) CellTiter-Glo luminescent
assay reagent (Promega) was added to each well and luminescence, which
reads out total ATP, was measured on a Cytation3 plate reader (BioTek).
Gene expression analyses
Expression data for DUX4-expressing cells were compiled from previously
published work for mouse C2C12 cells (Bosnakovski et al., 2008) and
human LHCNM2 cells (Choi et al., 2016). Additional data for C2C12
(Whiddon, 2017), human myoblasts (Geng et al., 2012) and human MB135
cells (Jagannathan, 2016) were downloaded from NCBI with the accession
numbers GSE87282, GSE33799 and GSE85461, respectively. RNA-seq
data were mapped and quantitated as described in Choi et al. (2016). Data
manipulation was performed in R (version 3.4.0) and visualizations were
created with pheatmap (version 1.0.8).
RTqPCR
RNA was isolated using Quick-RNA MiniPrep kit from Zymo Research
according to the manufacturer’s instructions. cDNA was synthetized from
0.75 μg of total RNAwith Verso cDNA Synthesis kit (Thermo Scientific).
qPCR was performed with Premix Ex Taq Master Mix (Takara) and
commercially available TaqMan probes [Gapdh: Mm99999915_g1;
Cdkn1a (p21): Mm00432448_m1, Applied Biosystems].
Western blots
Western blots were performed on total proteins isolated with RIPA buffer.
The following antibodies were used: rabbit anti-DUX4 (1:50 dilution, clone
RD47c, R&D Systems), mouse anti-p53 (1:1000, clone 1C12, lot 4, Cell
Signaling), horseradish peroxidase (HRP)-labeled mouse anti-GAPDH
(1:3000, HRP-60004, Proteintech), peroxidase-conjugated goat anti-rabbit
IgG (1:5000, 111-035-003, lot 127760, Jackson ImmunoResearch), goat
anti-mouse IgG-HRP (1:5000, sc-2005, lot L0312, Santa Cruz
Biotechnology).
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